MMS

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

Do you have questions about the EMA – Health Canada joint review process? MMS leaders break it down in our recent Perspe...
12/08/2025

Do you have questions about the EMA – Health Canada joint review process? MMS leaders break it down in our recent Perspectives article with four main takeaways and a discussion on how efficient the combined pathway really is for global sponsors.

We’ve seen as much as 70% of content overlap existed between the two submissions! Joint review like this can reduce redundancy and significantly accelerate timelines.

If you work on global submissions or plan to target both Europe and Canada, this overview helps you understand what’s changed, what works, and what you need to watch out for.

Read the full article: https://hubs.li/Q03Xd4tX0

With so much buzz around AI, it’s no surprise that sponsors are asking: “How are you using AI?” However, the better ques...
12/05/2025

With so much buzz around AI, it’s no surprise that sponsors are asking: “How are you using AI?” However, the better question might be: “How are you using AI to help me?”

At MMS, we approach these conversations by sharing perspective on where AI is currently valuable, like speeding up medical writing, anonymizing data, or supporting video review, for instance. We also make sure to discuss where the AI is still evolving, such as CRF development or automated statistical plan generation.

Read more and see what Sponsors really need from their CRO in terms of AI at https://hubs.li/Q03WQTGs0.

Breaking News: Former FDA, CRO, and industry leader Dr. Stephine Keeton has joined MMS as Senior Director of Biometrics!...
12/04/2025

Breaking News: Former FDA, CRO, and industry leader Dr. Stephine Keeton has joined MMS as Senior Director of Biometrics!

Chris Schoonmaker, Chief Operating Officer at MMS, shared, “Her appointment comes at an inflection point for our industry, as sponsors increasingly look for specialized partners who can guide them through complex data challenges and deliver high-quality, submission-ready results.”

Please give a warm welcome to Stephine in the comments, and read the entire announcement here: https://hubs.li/Q03WQ3qJ0

Biometrics is one of our leading growth areas in 2025 and it’s clear why! Our team recently released a webinar exploring...
12/03/2025

Biometrics is one of our leading growth areas in 2025 and it’s clear why! Our team recently released a webinar exploring how specialized data strategies designed by biometric, statistical, and data science experts can support sponsors in de‑risking development and advancing complex clinical programs.

One standout insight: when sponsors adopt tailored data frameworks early, they gain clearer visibility into trial feasibility and can align decision‑makers on a path forward with confidence.

Watch the full webinar to uncover how smarter data strategies drive value: https://hubs.li/Q03WpM730

The future of CRO partnerships demands a new conversation about value. MMS Vice President of Commercial Operations, Sand...
12/02/2025

The future of CRO partnerships demands a new conversation about value. MMS Vice President of Commercial Operations, Sandy Robbins, will take the stage at the Clinical Outsourcing Group CRO Summit today to challenge the status quo in CRO compensation models.

The keynote, “Reimagining CRO Compensation Models for Industry Advancement,” will explore how traditional procurement-driven models often misalign incentives and create inefficiencies.

Sandy will discuss:
✔️ How value-based pricing and outcome-linked incentives can reshape collaboration
✔️ The psychological barriers that limit innovation at large CROs
✔️ What sponsors can do to drive better results through smarter compensation strategies

By shifting the conversation from hourly rates to outcomes and impact, Sandy will make a compelling case for rethinking how clinical research partnerships are structured.

📅 December 2nd, 2:50 PM
👉 Review the full agenda here: https://hubs.li/Q03WpkQM0

Jobs alert! We’re currently seeking Medical Writers and Statistical Programmers who bring precision, passion, and drive ...
12/01/2025

Jobs alert! We’re currently seeking Medical Writers and Statistical Programmers who bring precision, passion, and drive to their work.

Apply now if you have the following skills:

✔️ A skilled communicator who can translate scientific research into compelling documents (for the medical writing role)
✔️ A seasoned statistical programming professional experienced with SAS, R, CDISC, and submission ready deliverables (for the programming role)
✔️ Comfortable collaborating in a global team, working across functions, and delivering high stakes outputs
✔️ Motivated by purpose, curiosity, and a commitment to advancing patients through precise and efficient development

Explore these opportunities and more: https://hubs.li/Q03WdqJg0

What an incredible evening at the TOPRA Awards!We’re honored to have been shortlisted for the Excellence Award in the Su...
11/28/2025

What an incredible evening at the TOPRA Awards!

We’re honored to have been shortlisted for the Excellence Award in the Support Category. Being recognized among such outstanding peers is a privilege and a testament to our team’s commitment to advancing regulatory science.

Congratulations to all the winners and finalists it was a fabulous evening celebrating innovation and collaboration in our industry!

There are only a few days remaining until our webinar on embedding QC into medical writing workflows begins! Join us to ...
11/28/2025

There are only a few days remaining until our webinar on embedding QC into medical writing workflows begins! Join us to discover practical tactics for aligning medical writers, QC specialists, and regulatory reviewers to tighten timelines and enhance accuracy.

Plus, gain insights from global medical writing and QC leaders, like Bhavya ChandreGowda, Sharon Oyetunde, Emily Scott, and Katrina O’Connor!

Register now, and don’t forget to share this link with your colleagues: https://hubs.li/Q03VNjHn0

Today and every day, we are thankful! Thankful for the brilliant people across MMS who lead with urgency, precision, an...
11/27/2025

Today and every day, we are thankful!

Thankful for the brilliant people across MMS who lead with urgency, precision, and heart.

Thankful for the Sponsors who trust us with their science and partner with us to bring new treatments forward.

Thankful for the shared commitment to improving lives through data and insights.

As we pause to reflect this Thanksgiving, we extend our gratitude to everyone who plays a role in advancing clinical research and building a healthier world. Wishing you a warm, restful holiday surrounded by all that matters most. Happy Thanksgiving, from the family to yours!

This playbook outlines actionable insights to help CMOs and biotech executives de-risk their programs, build investor tr...
11/26/2025

This playbook outlines actionable insights to help CMOs and biotech executives de-risk their programs, build investor trust, and secure funding faster. Have you read it yet?

Drawing on MMS expertise, the CMO investor playbook reveals strategies that you can apply right now to strengthen your pitch and clinical development plan.

Download now, and you’ll learn:

✅ Why investors value trial design as much as the science itself
✅ How biostatistics can de-risk your program and protect capital
✅ The hidden power of the CMO–statistician partnership
✅ Practical strategies and a readiness checklist to strengthen your pitch
✅ How simulation transforms trial planning into a fundraising advantage

Start here: https://hubs.li/Q03VMdXG0

This week, let's make a point to connect at the Annual Clinical Trials in Rare Diseases Europe! MMS is excited to have S...
11/25/2025

This week, let's make a point to connect at the Annual Clinical Trials in Rare Diseases Europe! MMS is excited to have Sal Siam, our Ireland-based Director of Business Development, walking the floor at the Marriott Munich City West, taking place in Germany on 26–27 November 2025.

MMS understands the importance of a customized regulatory strategy and the value of each data point when developing a new therapy for rare disease indications, and Sal is looking to connect with like-minded professionals and explore opportunities for collaboration. If you’re attending, message us directly or learn more about our rare disease experience here: https://hubs.li/Q03VPzgC0

See you in Germany! Review the event agenda here: https://hubs.li/Q03VPrMg0

Psychedelic therapies have emerged as one of MMS’s fastest growing therapeutic areas, and the opportunity has never been...
11/25/2025

Psychedelic therapies have emerged as one of MMS’s fastest growing therapeutic areas, and the opportunity has never been clearer! Our on demand webinar, "The Psychedelic Inflection Point: What Sponsors Need to Know Now,” explores how regulatory shifts, unmet medical needs in psychiatry and neuroimmunology, and the evolving clinical landscape are creating a meaningful opening for innovation.

Need one standout insight before you commit? Despite early regulatory hesitancy, recent precedent designations and agency engagement are enabling sponsors to structure programs around clear benefit-risk evidence and pathway alignment.

▶️ Watch the webinar to learn what smart development strategies look like, how to avoid common pitfalls when working in this space, and how to position your program for success: https://hubs.li/Q03VMjbJ0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMS:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards.